Abstract 1866P
Background
The aim of this study was to compare sexual health between young breast cancer survivors and healthy young women without history of cancer, to better analyse the impact of breast cancer diagnosis and treatment on sexual health.
Methods
We conducted a cross-sectional study including all young breast cancer patients (≤40 year-old) referred for radiotherapy between 2017 and 2021. Patients were asked to fill in the Female Sexual Function Index (FSFI) in its validated Arabic translated version. A comparable cohort of young healthy women was recruited to fill in the same questionnaire. Sexual scores were calculated for both groups and statistically compared.
Results
A total of 102 young breast cancer patients (BC group) and 53 young healthy women (control group) were included in this study. Only 39.2% of breast cancer patients answered the questionnaire. Ninety-seven percent of patients underwent chemotherapy. Adjuvant endocrine therapy was prescribed for 77% of patients, of whom 97% underwent ovarian function suppression. All patients received adjuvant hypofractionated radiotherapy. Mean FSFI score was 24.01 (2.4-33) in the BC group versus 28.88 (23.8-34.4) in the control group (p=0.000). Two patients declared having unpleasurable sexual activities before their diagnosis. Sexual dysfunction (FSFI score < 26,55) was reported in 55% and 20%, respectively in the BC and control group (p=0.001). Mean desire score was 3.58 vs 4.08 (p=0.016), respectively in the BC group and the control group. Ninety-two percent of breast cancer patients suffered from hypoactive sexual desire disorder (desire score <5), versus 87% in the control group (p=0.35).
Table: 1866P
Female Sexual Function Index questionnaire scores
Domain | Breast cancer group | Control group | P value |
Desire | 3.58 | 4.08 | 0.016 |
Arousal | 3.71 | 4.56 | 0.001 |
Lubrification | 4.15 | 5.16 | 0.00 |
Orgasm | 4.23 | 4.97 | 0.007 |
Satisfaction | 4.44 | 5.49 | 0.00 |
Pain | 3.85 | 4.62 | 0.008 |
Conclusions
This study showed a significant alteration of sexual function in young breast cancer survivors when compared with a control group. Assessment and management of sexual dysfunction should become a standard practice, in order to improve quality of life and sexual health in young breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands
Presenter: Ellis Slotman
Session: Poster session 05
1595P - Incidence and characterization of end-of-life (EoL) systemic anticancer therapy (SACT) in melanoma patients (pts): A monocentric experience
Presenter: Silvia Buriolla
Session: Poster session 05
1596P - Exploring the economic impact of palliative care in oncology at the end of life
Presenter: Sarah Gomes
Session: Poster session 05
1597P - Improving in-hospital end-of-life care (EOLC) for oncology patients in a tertiary cancer centre
Presenter: Conor Moloney
Session: Poster session 05
1598P - Differences in referral patterns to the palliative care team among specialized physicians in patients with terminal cancer
Presenter: Hyun Jeong Shim
Session: Poster session 05
1599P - Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study
Presenter: Alessandro Leonetti
Session: Poster session 05
1600P - Sarcopenia, depression, and poor health perception among cancer patients registered in an oncology center in Pakistan
Presenter: Sobia Yaqub
Session: Poster session 05
1601P - Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy
Presenter: Gurkan Guner
Session: Poster session 05
1602P - Simulation training for compassionate extubation in the pediatric intensive care unit
Presenter: Nicole Fernandez
Session: Poster session 05
1603P - The ability of the LACE index to predict 30-day readmissions in oncology patients
Presenter: Burcu Ulas Kahya
Session: Poster session 05